Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 1/20 | 0.47 |
| ▸ | MPO | P05164 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.37 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8807524 | 0.84 | MAPT (0.55) | METMPOSYKSMN1; SMN2CYP1A2 | |
| SCHEMBL6701279 | 0.84 | MET (0.53) | METMPOSYKSMN1; SMN2MRGPRX4 | |
| SCHEMBL6701302 | 0.75 | KMT2A (0.49) | SMN1; SMN2CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4639191 | 0.75 | MAOB (0.59) | METMPOSMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL487777 | 0.71 | MET (0.83) | METMPOSMN1; SMN2 | |
| SCHEMBL22114118 | 0.71 | TAAR1 (0.40) | SMN1; SMN2CYP3A4ALDH1A1GAATAAR1 | |
| SCHEMBL487572 | 0.70 | MET (0.73) | METMPO | |
| SCHEMBL13577267 | 0.70 | MET (0.46) | METMPOSMN1; SMN2TAAR1PKM | |
| SCHEMBL26151206 | 0.70 | MET (0.46) | METMPOSMN1; SMN2PKM | |
| SCHEMBL27547295 | 0.70 | MAPT (0.67) | SMN1; SMN2CYP3A4ALDH1A1GAAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6723749-B2 | TREATING BACTERIAL INFECTIONS | SMITHKLINE BEECHAM CORPORATION | 2004-04-20 | — | — | US | disclosed |
| US-20040058988-A1 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC | 2004-03-25 | — | — | US | disclosed |
| EP-1318803-A1 | FATTY ACID SYNTHASE INHIBITORS | SmithKline Beecham Corporation (US) | 2003-06-18 | — | — | EP | disclosed |
| WO-2002009688-A1 | FATTY ACID SYNTHASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058988-A1 | FATTY ACID SYNTHASE INHIBITORS | FASN, FADS1, FADS2 | MET 1344/4885MPO 2901/4885SYK 3963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.